Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Depressive Disorder, Major

• Feasibility of Conducting a Clinical Trial Assessing Efficacy of Lactate as Adjunctive Therapy in Patients With Major Depressive Disorder
• Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
• Psilocybin rTMS for Treatment Resistant Depression
• The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN)
• Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
• Positioning of Esketamine Treatment in the Real-world Management of Depression
• A Randomized Neuroimaging Trial of Psilocybin in Depression
• PEA vs. Placebo for Major Depression
• Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
• Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
• Psychopharmacotherapy for Depressive Patients
• Study to Assess the Safety and Effectiveness of NMRA-335140-501
• Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
• Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
• Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
• Study of ALTO-300 in MDD
• Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation
• Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain With Toludivenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
• 5-HTP and Creatine for Depression R33 Phase
• Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
• Synaptic Imaging and Network Activity in Treatment Resistant Depression
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
• Intradermal Acupuncture Versus Sham Acupuncture and SSRI for Treating Adolescents With Major Depressive Disorder
• Glutamate Emotion Memory Study
• Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders
• The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
• The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
• Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
• A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Major Depressive Disorder With One Prior Treatment Failure
• D-Cycloserine+iTBS PK Study
• The Efficacy and Cerebral Mechanism of Intradermal Acupuncture for Major Depressive Disorder
• Phase 2b Study of ALTO-100 in MDD
• N2O for Acute Suicidality and Depression in the ED
• [18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
• Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
• Psilocybin for Major Depressive Disorder
• An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain
• Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
• SAGE-217 Pharmacokinetics (PK) and Safety Study Pediatric Participants With Major Depressive Disorder (MDD)
• INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
• IM and IV SPL026 Drug Product in Healthy Participants
• Clinical Predictors of Intravenous Ketamine Response in Treatment-Resistant Depression
• Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
• Efficacy and Safety of Intradermal Acupuncture for Major Depressive Disorder
• Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
• PET Synaptogenesis After Psilocybin In DEpression Recovery
• Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
• Effect of SSRIs on Response to Psilocybin Therapy
• A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
• D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT)
• Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents
• Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
• VA Aripiprazole vs Esketamine for Treatment Resistant Depression
• SPL026 With or Without SSRIs in Participants With MDD
• A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
• Defining Neurobiological Links Between Substance Use and Mental Illness
• SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
• Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
• RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)
• Multi-factor Model Constraction for Early Warning and Diagnosis of MDD
• Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive Disorder
• A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
• An EEG Study of Intravenous Ketamine for Major Depression Disorder
• Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
• Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Treatment for Major Depressive Episode
• Chinese Longitudinal and Systematic Study of Bioplar Disorder
• A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
• Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
• ANC-501 in the Treatment of Adults With Major Depressive Disorder
• Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
• Measurement-Based Care Vs. Standard Care for Major Depressive Disorder
• Anti-suicidal Effects of Buprenorphine In Depressed Individuals
• ALTO-100 in Major Depressive Disorder
• Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
• Assessing SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
• Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
• Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
• Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
• Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
• Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia
• A Study of a Psilocybin Analog (CYB003) in Participants With Major Depressive Disorder
• The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
• A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
• Antidepressant Effects of Nitrous Oxide
• Acupuncture Therapy Based on Biological Specificity of Acupoints for Major Depressive Disorder
• Intradermal Needle Therapy for Major Depressive Disorder
• Effects of a Single Dose of Amisulpride on Functional Brain Changes
• Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
• Pentoxifylline for Treatment of Resistant Major Depression
• Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
• The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects
• Effects of Ghrelin Administration on Dopamine and Effort
• Predictors of Cognitive Outcomes in Geriatric Depression
• Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder
• Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints
• Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.1. (Pharmacological Manipulation)
• Psilocybin-assisted CBT for Depression
• RESET-medication Glucocorticoid Receptor (GR) Blockade as Disease Modifying Treatment for Depression With Childhood Trauma
• The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling
• Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adults With Major Depressive Disorder (MDD)
• A Study of HS-10353 in Chinese Participants.
• KAP for Depression in Abstinent Opioid Users
• Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder
• Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
• ALTO-300 in Depression (ALTO-300-004)
• A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive Disorder
• A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment
• A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
• NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
• A Study of Xiongdan Wan Treating Depression
• ALTO-300 in Depression
• ALTO-100 in MDD and/or PTSD
• Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities
• A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
• An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
• Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
• The Role of Neuromodulation Technique In Depression Disorder
• Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets
• Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression
• Cannabinoids as a Treatment for Insomnia in Major Depression
• The Phosphodiesterase 5 Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients
• Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
• Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
• Sevoflurane for Treatment-Resistant Depression
• Aβ Dynamics in LLMD
• Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
• The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
• Safety and Tolerability of GATE-251 in Normal Human Volunteers
• Targeting IL-17A for Treatment-Resistant Depression
• Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder
• Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder
• Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
• An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients
• A Clinical Trial of Adjunctive PRAX-114 in Participants With Major Depressive Disorder
• Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy
• A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
• ECT vs. Esketamine
• Open Label Study to Assess the Safety of REL-1017 for Major Depressive Disorder
• A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
• A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
• Reward Emotion Learning and Ketamine Study
• Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder
• Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)
• Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray
• A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
• Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
• A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
• Clonidine to Prevent Delirium After Electroconvulsive Therapy.
• XEN1101 for Major Depressive Disorder
• Antidepressant Effects of TS-161 in Treatment-Resistant Depression
• The Effect of Celecoxib on Neuroinflammation in MDD
• TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic
• The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients
• The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
• Stellate Ganglion Block for Major Depressive Disorder.
• ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION
• Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
• The Modulatory Role of Communicated Treatment Rationale on Treatment Expectation Effects in Depression.
• Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
• Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
• Clinical Study of GH001 in Depression
• Antidepressant Response in Older Adults With Comorbid PTSD and MDD
• A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
• Maternal Mental Health Trial
• SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
• A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
• Dexmedetomidine Adjuvant Treatment for Depressed Patients Undergoing ECT
• NMDA Modulation in Major Depressive Disorder
• Open-Label Safety Study of AXS-05 in Subjects With TRD
• The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density
• the Safety, Tolerability, and Pharmacokinetics Study of HEC113995
• Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine
• Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
• Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers
• Mechanistic Evaluation of Response in TRD (MERIT)
• The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression
• Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects
• The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
• The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects
• Imaging Neural Correlates of Ketamine Using PET/MR
• PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
• Effect of Self-administered tDCS in Patients With MDD
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With S
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
• PKC as Serum Biomarkers for Depression
• Optimization of Diagnosis and Treatment of Depression Based on Multidimensional Clinical Assessment Classification
• A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
• A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
• Bear Bile Pill as add-on the Treatment of MDD
• Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
• A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder
• Vortioxetine for Treatment of Depressive Mood and Alcohol Use
• Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients
• A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
• A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
• Ketamine or Placebo in Patients With Major Depression and Advanced Cancer
• A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder
• Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
• A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
• eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
• Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients
• A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
• Combination of Novel Therapies for CKD Comorbid Depression
• The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients
• The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)
• 5-HTP and Creatine for Depression
• Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
• Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
• Study of Desvenlafaxine in Treating Major Depressive Disorder.
• Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)
• Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
• A Study of MD-120 in Patients With Depression
• The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients
• A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depres
• Study of Naltrexone-Induced Blockade of Antidepressant Effects
• Treatment for Cognitive Impairment in Depression
• Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes
• Does rTMS Induce Synaptic Plasticity?
• Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression
• Vortioxetine in Patients With Depression and Early Dementia
• Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
• Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
• Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses
• The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy
• A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
• Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder
• Study in Major Depressive Disorder With BTRX-335140 vs Placebo
• Comparison of Anyu Peibo With Placebo in Treatment of MDD in China
• A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features
• The BIomarker Guided Study for Depression
• Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
• Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent
• Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
• The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression
• Antidepressant Trial With P2X7 Antagonist JNJ-54175446
• Opiate Suicide Study in Patients With Major Depression
• CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
• Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality
• Ketamine for Mood Disorders With Suicidal Ideation
• Ketamine Treatment Effects on Synaptic Plasticity in Depression
• The Antidiabetic Metformin as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients
• Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.
• A Study of JNJ-61393215 in the Treatment of Depression
• The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.
• A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
• Open-Label Safety Study of AXS-05 in Subjects With Depression
• Clinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory Symptoms
• Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
• Ketamine for Treatment Resistant MDD
• A Trial of AXS-05 in Patients With Major Depressive Disorder
• Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder
• A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder
• Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2)
• The Role of HNKs in the Antidepressant Effect of Ketamine
• Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
• Neurobiological Processing of Emotions in Major Depression
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2)
• Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
• Adjunctive D-Cycloserine in Major Depressive Disorder
• Nitrous Oxide for Major Depressive Disorder
• Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment
• Brain Insulin Resistance in Mood Disorders
• Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders
• Study on the Effect of PRKCB1 Modulating Inflammatory Factors and the Role for Developing Major Depressive Disorder
• Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
• Scopolamine in Healthy Volunteers
• RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode
• Nitrous Oxide for the Treatment of Major Depressive Disorder
• LSD Therapy for Persons Suffering From Major Depression
• A Study of Psilocybin for Major Depressive Disorder (MDD)
• A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
• Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery
• Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
• A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
• Study With Vortioxetine on Emotional Functioning in Patients With Depression
• A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
• Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression
• Treating Smokers With Mental Illness
• A Relative Bioavailability Food Effect Study of LY03005
• Contact: Developing New Clinical Management Strategies
• Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
• Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder
• Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
• Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
• A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia
• Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression
• L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
• Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
• Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets
• The Object of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepre
• Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
• A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
• Nitrous Oxide- Suicidal Ideation
• A Study of LY03005 vs Pristiq
• AGN-241751 in the Treatment of Major Depressive Disorder
• Ketamine for Major Depressive Disorder
• Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept
• A Study of Brexpiprazole in Patients With Major Depressive Disorder
• A Study to Evaluate SAGE-217 in Subjects With Bipolar I/II Disorder With a Current Major Depressive Episode - Part A
• Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
• Ketamine Versus Electroconvulsive Therapy in Depression
• A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
• Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
• Development of Pregnenolone as a Treatment for Depression R61
• A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
• A Study in Patients With Major Depressive Disorder
• A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression
• Modafinil's Effects on Cognition in Remitted MDD
• Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
• A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
• A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine
• Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
• Assessing Symptomatic Clinical Episodes in Depression
• AGN-241751 in the Treatment of Major Depressive Disorder
• Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes
• Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
• Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder
• Study of Rapastinel as Monotherapy in Patients With MDD
• A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
• The Study of Mindfulness-based Cognitive Therapy and Major Depressive Disorder
• Role of Pentoxifylline as an Adjuvant Therapy for Adult Patients With Major Depressive Disorder
• Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
• Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
• Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA)
• A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
• A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
• Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
• Cycloserine rTMS Plasticity Augmentation in Depression
• A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
• Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers
• The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder
• A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
• Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.
• Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)
• Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
• NMDA Modulation in Major Depressive Disorder in Late- Life
• To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD
• The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression
• A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder
• Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
• Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
• A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder
• Simplified Cognitive Behavioral Therapy for Generalized Anxiety Disorder and Depression
• A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepress
• Stepped Care aiTBS 2 Depression Study (Ghent)
• Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
• Fecal Microbiota Transplantation in Depression
• Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.
• Ketamine as an Adjunctive Therapy for Major Depression
• A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
• Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
• Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression
• Creatine for Treatment of Depression Associated With Type 2 Diabetes
• BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
• A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
• Cognitive Dysfunction in MDD Patients
• Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Partici
• Comparison of Anyu Peibo With Placebo in Treatment of MDD，Ⅱb
• Effects of Psilocybin in Major Depressive Disorder
• The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
• Salicylic Augmentation in Depression
• Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD
• Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)
• Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders
• Efficacy and Safety of Duloxetine Among Individuals With Depressive Disorder in a 12 Weeks Trial
• ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
• Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
• Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD
• Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy
• 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participa
• A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder
• Rapid Antidepressant Effects of Leucine
• AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
• Neurobiology of Treatment Responses in MDD
• Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
• Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
• Open Label Ketamine Treatment for Major Depressive Disorder in Veterans
• THINC-it Vortioxetine - Sensitivity to Change
• Endogenous Opioid Modulation by Ketamine
• Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
• 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participa
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
• A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
• NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
• Investigation of Antidepressant Efficacy of Oral Ketamine Treatment
• Pilot BA Study of New LY03005 vs Pristiq
• Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
• Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
• N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
• Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine
• Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
• Burst Suppression Anesthesia for Treatment of Severe Depression
• Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
• Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression
• Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
• A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder
• Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
• Measurement-based Care for Depression in Resource-Poor Settings
• Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
• A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder
• Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
• Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone
• The UTHealth Ketamine Project
• Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
• Multimodal Imaging of ECT Effects
• Treatment Outcome in Major Depressive Disorder
• A Trial of Dextromethorphan for Treatment of Major Depressive Disorder
• Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment
• Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)
• Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)
• Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators
• Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment
• Ketamine Anesthesia for Improvement of Depression in ECT
• Personalized Indications for CBT and Antidepressants in Treating Depression
• The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
• A Study of L-DOPA for Depression and Slowing in Older Adults
• A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
• Imaging SV2A in Mood Disorders
• A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder
• Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
• Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
• Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)
• A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
• Study of NSI-189 for Major Depressive Disorder
• Study of Neural Responses Induced by Antidepressant Effects
• The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy
• A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia
• Open-Label Placebo for the Treatment of Depression
• Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression
• Ketamine for Relapse Prevention in Recurrent Depressive Disorder
• Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder
• Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder
• Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
• Intra-nasal vs. Intra-venous Ketamine Administration
• Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers
• Efficacy of Trial-Based Cognitive Therapy and Behavioral Activation in Treatment of Depression
• Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa
• Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.
• MetAbolism vaRiability of VEnLafaxine
• Ketamine Infusion for Adolescent Depression and Anxiety
• Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture
• Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
• Predictors of Treatment Response in Late-onset Major Depressive Disorder
• Ketamine for Depression: An MRI Study
• Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients
• Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
• Study of Ibuprofen Effects on Brain Function
• An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
• Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
• The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression
• A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder
• The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD
• An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
• Noradrenergic Activity, Cognition and Major Depressive Disorder
• Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment
• Trial of Levomilnacipran in Geriatric Depression
• Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
• A Study of Intermittent Doses of CERC-301 in MDD
• eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients
• Adjunct Minocyline in Treatment-resistant Depression
• Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease
• Predictors of the Outcome of Late Life Depression
• A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
• A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)
• Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
• MRI Studies of Emotion in Depression
• Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms
• miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome
• Clinical Registry of Patients Under Treatment With Atypical Antipsychotics
• A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise
• Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
• A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
• Comparison of Yuxintine With Placebo in Treatment of MDD
• A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
• Comparison of Anyu Peibo With Placebo in Treatment of MDD
• Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
• Improving Therapeutic Learning in Depression: Proof of Concept
• Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
• Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers
• Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder
• Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
• 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
• Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder
• Characterization of the Prosocial and Prosexual Effects of GHB
• Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
• Connectivity Affecting the Antidepressant REsponse Study
• Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis
• Microbiome of Depression & Treatment Response to Citalopram
• Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder
• A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
• Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
• Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
• Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder
• Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
• Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
• A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)
• Integral Assessment in Unipolar Depression
• Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
• Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care.
• Bupropion for Depression in ESRD Patients on Hemodialysis
• Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
• Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain
• Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
• Ketamine Infusions for Major Depression Disorder
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
• Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
• Clinical Study of Generic and Brand Bupropion in Depression
• Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
• Open Label Extension for GLYX13-C-202, NCT01684163
• Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
• Comparison of Orcinoside With Placebo in Treatment of MDD
• The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial
• Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
• Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
• Buprenorphine Used With Treatment Resistant Depression in Older Adults
• Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
• Biomarkers of Fast Acting Therapies in Major Depression
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
• Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
• Study to Treat Major Depressive Disorder (MDD) With a New Medication
• A Long-Term Safety Study of ALKS 5461
• Nitrous Oxide as Treatment for Major Depression - a Pilot Study
• Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
• A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide
• Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression
• Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
• Ketamine Alcohol (in Treatment-Resistant Depression)
• OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
• Trazodone Once a Day in Major Depression Disorder
• A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
• Developing New Clinical Management Strategies
• Ketamine in Adolescents With Treatment-Resistant Depression
• Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
• A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants
• The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy
• Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT)
• Safety, Tolerability and Pharmacokinetics Study of LY03005
• Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)
• Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?
• An Open Prospective Trial of IV Ketamine in Suicidal Adolescents
• Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
• PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011
• Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode
• The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression
• Imaging Dopamine Release in Depression
• The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives
• Objective Diagnostic Markers and Personalized Intervention in MDD Patients
• Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
• Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
• Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
• Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
• Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
• Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder
• A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder
• Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
• Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
• Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)
• A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder
• Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
• Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study
• Ketamine for Suicidality in Bipolar Depression
• Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
• Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder
• A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults
• A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment
• Mechanisms of Antidepressant Non-Response in Late-Life Depression
• Oral Multiple-dose Study in Patients With Major Depressive Disorder
• Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
• Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder
• Effects of Treatment on Decision-making in Major Depression
• Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients
• Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
• Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder
• Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression
• Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
• Nuedexta in Treatment-Resistant Major Depression
• Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
• Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
• Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
• Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder
• A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
• Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy
• Naltrexone for Antipsychotic-Induced Weight Gain
• Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?
• Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
• Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
• Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
• Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
• An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms
• A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
• Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI
• A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing
• A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
• Omega 3 FA Supplements as Augmentation in the Treatment of Depression
• Neurobiological Bases of Placebo Response in Major Depressive Disorder
• A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder
• A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression
• Algorithm Guided Treatment Strategies for Major Depressive Disorder
• Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression
• Efficacy and Safety Curcumin in Depression
• Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
• Double-Blind Treatment of Major Depressive Disorder With Vilazodone
• Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
• Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression
• Agomelatine in Depressed Patients With Fibromyalgia
• Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
• A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
• A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
• Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
• Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer
• Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
• Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
• Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
• Riluzole Augmentation Pilot in Depression (RAPID) Trial
• An Investigation of Early Life Stress and Depression
• Ketamine in the Treatment of Suicidal Depression
• Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder
• Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
• PET Imaging of mGLuR5 With Drug Challenge
• Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
• Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
• Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression
• Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
• Canadian Biomarker Integration Network for Depression Study
• Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder
• A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
• Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers
• A Study of Ketamine in Patients With Treatment-resistant Depression
• Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)
• Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder
• Vilazodone for Treatment of Geriatric Depression
• Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder
• Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
• LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression
• Lexapro®'s Efficacy After Dose Escalation in Remission Study
• Ketamine Infusion for Treatment-resistant Major Depressive Disorder
• A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
• Study of Ketamine as an Antidepressant in Major Depressive Disorder
• Safety and Efficacy of Vilazodone in Major Depressive Disorder
• Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries
• Major Depressive Disorder - Understanding The Link Between The Brain And The Heart
• Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
• Pioglitazone in Patients With Mood Disorders
• Ketamine in the Treatment of Depression
• Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
• Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks
• Efficacy Study of Botox for Depression
• Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
• Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder
• Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital
• A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
• Effect of Antidepressants on White Matter Structure
• Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder
• A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
• Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
• Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
• A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
• A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture
• Stimulant Enhancement of Well-Being Therapy for Depression
• Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features
• Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
• Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
• Safety and Efficacy of Vilazodone in Major Depressive Disorder
• Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
• Neurocognition and Work Productivity in Major Depressive Disorder (MDD)
• Randomized Double Blinding Controlled Study on" Jia Wei Xiao Yao Jiaonang" Treating Mild to Moderate Major Depressive Disorder
• Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
• A Study to Evaluate the Effect of Clarithromycin on LY2216684
• A Study to Evaluate the Effect of Genotype on LY2216684
• Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder
• Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement
• ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
• Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder
• Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder
• Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
• A Study of Ketamine as an Antidepressant
• Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
• MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
• SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
• Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
• Wake Therapy in the Treatment of Depression
• Aripiprazole for the Augmentation of Antidepressant Therapy
• Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
• Sustaining Remission of Psychotic Depression
• Exploring Biomarkers for Depression
• Major Depressive Disorder With Mixed Features - Extension
• Major Depressive Disorder With Mixed Features
• Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
• VA Augmentation and Switching Treatments for Improving Depression Outcomes
• Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
• Lithium Versus Paroxetine in Major Depression
• Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
• Study Using Pregnenolone to Treat Bipolar Depression
• Buprenorphine for Treatment Resistant Depression
• Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
• Treatment Resistant Geriatric Depression in Primary Care
• Inflammatory Markers and Cognitive Function in Major Depression
• A Study to Evaluate the Effect of Food on LY2216684
• A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
• ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD
• Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
• A Study of LY2216684 in Healthy Participants
• Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
• A Study of LY2216684 in Healthy Females
• A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
• A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
• A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
• A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
• A Study of LY2216684 in Participants With Major Depression Disorder
• Electroencephalography (EEG) Signal Processing
• Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
• Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
• Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
• Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
• Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
• Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
• Neurophysiologic Monitoring of Antidepressant Treatment
• The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope
• Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
• Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
• Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder
• Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
• A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine
• Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
• Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
• Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder
• Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression
• Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder
• The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor (BDNF) in Depressed Elders
• Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
• Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
• Intranasal Ketamine in Treatment-Resistant Depression
• A Study in Prevention of Re-emergence of Depression Symptoms
• A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
• Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression
• A Study of the Effect of LY2216684 on Lorazepam
• Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder
• A Study of LY2216684 and Digoxin in Healthy Subjects
• A Study of LY2940094 in Major Depressive Disorder
• A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
• A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
• A Study of LY2216684 and Warfarin in Healthy Subjects
• A Study of LY2216684 and Theophylline in Healthy Subjects
• A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
• N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
• Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
• Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
• The Effects of Dopamine on Reward Processing
• A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
• Lexapro for Major Depression in Patients With Epilepsy
• Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
• A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
• A Study of LY2216684 in Participants With Impaired Hepatic Function
• Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study
• Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
• Oxytocin Add-on for Stable Depressed Patients
• Pharmacogenomics Studies of Antidepressants
• Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
• A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
• Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)
• Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
• Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder
• A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
• Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)
• A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
• A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
• Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
• Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)
• Creatine Augmentation in Veterans With SSRI-Resistant Major Depression
• A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
• Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
• Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
• A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)
• A Safety Study in Participants With Major Depressive Disorder
• A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
• Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
• Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
• A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
• Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.
• Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder
• 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
• A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
• Study of Depression-Ketamine-Brain Function
• Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
• Safety and Pharmacology Study of BMS-866949
• To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
• Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
• Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)
• Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder
• A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
• Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
• Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
• Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
• Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
• Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder
• Strategic Use of New Generation Antidepressants for Depression
• Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder
• Neural Responses and Dysphoria: Modulation by a Pharmacological Probe
• Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression
• Rhodiola Rosea Therapy of Major Depressive Disorder
• A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
• Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
• Biomarkers for Outcomes In Late-life Depression (BOLD)
• Early Prediction of Fluoxetine Response
• A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
• Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
• A Study in Depression and Associated Painful Physical Symptoms
• Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
• Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
• A Study of the Neurobiology of Depression
• Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
• A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder
• Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
• Safety Study of F2695 SR in Major Depressive Disorder
• Efficacy Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder
• PET Biomarkers in Treatment Resistant Depression
• First Time in Human Study
• fMRI Study of Treatment Changes in Major Depression
• Effect of Curcumin as Nutraceutical in Patients of Depression
• AZD7268 Safety and Tolerability Study
• Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis
• A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms
• Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment
• Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans
• The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
• This is a Study to Determine the Antidepressant Effects of AZD6765
• SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
• A Study of Patients With Major Depressive Disorder and Residual Apathy
• Brain Imaging of Quetiapine Response in Anxious Depression
• N-methylglycine (Sarcosine) Treatment for Depression
• Clinical Study to Test a New Drug to Treat Major Depression
• Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
• Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
• Escitalopram (Lexapro) for Depression MS or ALS
• Study of Supplementation of Antidepressants With Fish Oil to Improve Time to Clinical Response
• The Role Of Omega-3 Fatty Acids In Adolescent Depression
• A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder
• Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
• Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms
• Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
• Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
• Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
• Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression
• Assessment of Cognitive Functioning Before and After Treatment With Duloxetine
• Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder
• Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression
• Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients
• Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)
• Brain Imaging Techniques That Predict Antidepressant Responsiveness
• Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
• Safety and Efficacy Study in Patients With Major Depressive Disorder
• Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder
• Duloxetine for Major Depression in Peri-/Postmenopausal Women
• Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women
• Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
• Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
• A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
• A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
• Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
• Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
• Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression
• Transcranial Direct Current Stimulation (tDCS) Augmentation by D-Cycloserine as a Treatment for Depression
• Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder
• Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)
• Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
• Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
• Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
• Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram
• A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
• A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
• Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
• A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
• Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
• Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
• Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)
• Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
• Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
• Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
• Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression
• An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients
• Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
• Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder
• Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
• Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder
• Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
• A Study in Adult Patients With Major Depressive Disorder
• Physiologic Monitoring of Antidepressant Treatment Response
• Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
• Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
• Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression
• Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD
• Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine
• AZD6765 Severe Major Depressive Disorder (MDD) IV
• A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
• Optimization of IV Ketamine for Treatment Resistant Depression
• Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder
• Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
• Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
• Electroencephalography (EEG) Biomarkers of Response in Depression
• Quetiapine in the Treatment of Psychotic Depression - a Pilot Study
• fMRI Studies of Emotional Brain Circuitry in People With Major Depression
• Stress Generation and Recurrent Depression: The Role of Differential Treatment Response
• Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression
• Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
• A Study of CX157 (TriRima) for the Treatment of Depression
• Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
• A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
• Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder
• Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)
• Treatment of Schizoaffective Disorder Using Mifepristone
• Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression
• Cysteamine Therapy for Major Depressive Disorder
• Fluoxetine vs. Brief Psychotherapy for Major Depression
• Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
• Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
• Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)
• Switching to Duloxetine in Patients With Depression
• Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults
• Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
• International Study to Predict Optimised Treatment - in Depression
• TC-5214 as add-on the Treatment of Major Depressive Disorder
• Quetiapine in Co-Morbid Depressive and Anxiety Disorders
• A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
• Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)
• Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)
• A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome
• Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
• Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)
• Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
• Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
• Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
• Escitalopram in Adult Patients With Major Depressive Disorder
• Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)
• Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder
• A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
• Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression
• Efficacy Study of Escitalopram for Depression in Patients With Diabetes
• Ketamine Frequency Treatment for Major Depressive Disorder
• A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
• A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
• Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
• Antidepressant Therapy for Bipolar II Major Depression
• A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
• A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
• Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
• Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
• An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
• Brain Mechanisms and Targeting Insomnia in Major Depression
• Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression
• Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder
• A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
• Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
• Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety
• Behavioral Insomnia Therapy For Those With Insomnia and Depression
• Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder
• Duloxetine for the Treatment of Postpartum Depression
• Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?
• Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder
• The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
• Treatment of Mood and Marriage Study (TOMMS)
• Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
• Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features
• Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
• Antidepressant Therapy in Treating Bipolar Type II Major Depression
• Dose-finding Study With Lu AA24530 in Major Depressive Disorder
• Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes
• Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy
• Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
• Project to Improve Symptoms and Mood in People With Spinal Cord Injury
• Combining Medications to Enhance Depression Outcomes
• Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
• A Safety, Efficacy and Tolerability Study of SEP-225289
• The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
• Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms
• Effect of Intranasal Insulin on Depressive Symptoms in Major Depressive Disorder
• A Study of GW856553X For the Treatment of Depression
• Optimal Duration of Olanzapine Add-on Therapy in Major Depression
• The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
• A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
• Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones
• Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months
• Patient Tolerability Study of GSK163090
• The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
• A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
• SA4503 8-Week Study in Major Depressive Disorder (MDD)
• Continuation Ketamine in Major Depression
• Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients
• A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
• Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
• Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
• An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache
• An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
• Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder
• Do Antidepressants Induce Metabolic Syndromes METADAP Study
• Does Dual Therapy Hasten Antidepressant Response?
• Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
• Duloxetine for Perimenopausal Depression
• Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression
• Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder
• Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
• Cimicoxib for the Treatment of Major Depression (SECIM)
• Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home
• Duloxetine Versus Paroxetine for Major Depression
• Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
• Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)
• Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)
• Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)
• Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients
• Antidepressant Effects of NR2B in Major Depression
• Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder
• Brain GABA Levels and Treatment Response in Major Depressive Disorder
• A Study of Infliximab for Treatment Resistant Major Depression
• A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
• A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks
• Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
• Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder
• Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
• St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety
• The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder
• Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
• A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
• Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones
• Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder
• Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
• Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder
• Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)
• Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients
• Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
• A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
• Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
• Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression
• Prozac Treatment of Major Depression: Discontinuation Study
• A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
• Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
• Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.
• MDD POC Study GSK372475 Subjects Depressive Disease
• A Study for Participants With Major Depression
• Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
• An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
• Evaluation of the Effects of Duloxetine on Norepinephrine
• Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
• Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
• Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
• D-cycloserine for Major Depressive Disorder
• Study for Evaluating Different Methods of Measuring Depression Treatment Response
• A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients
• Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
• Dichotic Listening as a Predictor of Medication Response in Depression
• A Double-blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression
• Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
• Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide
• Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
• Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder
• Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
• Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
• Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
• A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence
• Preventing Depression Recurrence in Diabetes
• Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients
• STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse
• Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
• A Local Register Study For Major Depression Of Paroxetine Controlled Release
• A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
• Imaging Predictors of Treatment Response in Depression
• Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
• An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
• Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
• Biological Markers of Response to Treatment in Major Depressive Disorder
• An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
• Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine
• Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents
• Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
• Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
• A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder
• Functional Neuroimaging in Depression
• A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
• A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.
• Pilot Study of Duloxetine in Psychological Resilience
• Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
• Acamprosate in Alcoholics With Comorbid Anxiety or Depression
• Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
• Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders
• Interpersonal Psychotherapy for Severely Depressed Inpatients
• Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
• Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
• Nicotinic Receptor Augmentation of SSRI Antidepressants
• Sexual Functioning Study With Antidepressants
• AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment
• Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
• Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder
• Memory Functioning and Antidepressant Treatment
• Treatment of Depression Following Multiple Brain Tests
• Dichotic Listening as a Predictor of Medication Response in Depression
• Are Two Antidepressants a Good Initial Treatment for Depression?
• Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression
• Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors
• Mineralocorticoid Receptor in the Treatment of Severe Depression
• The Effectiveness of Idazoxan in Treating TRD
• Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder
• A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression
• Cellular Aging and Neurobiology of Depression Study
• Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT
• Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression
• Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression
• Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response
• Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
• Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
• A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)
• Clinical Pharmacogenomics of Antidepressant Response
• Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group
• Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder
• Essential Fatty Acids for Major Depression
• Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
• Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
• Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents
• CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.
• Magnetic Resonance Imaging Study of Geriatric Depression
• Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder
• Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder
• A Study of Omega-3 as a Treatment for Major Depression
• Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
• Wellbutrin XL, Major Depressive Disorder and Breast Cancer
• Investigation of a Combination Treatment of Escitalopram and rTMS
• A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety
• Study of Medication and Placebo Response in Major Depression
• Estrogen and Perimenopausal Depression
• Integrated Treatment for Cocaine and Mood Disorders - 1
• Safety Study of ORG 34517 for Major Depression With Psychotic Features
• Impact of Caregiver Depression on Asthma in the Child
• Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse
• Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study
• Abilify as an Adjunctive Treatment for Refractory Depression
• Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression
• A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression
• Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression
• A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
• Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
• Characterizing Psychological Consequences of Childhood Trauma
• Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?
• Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
• Thyroid Medication and Antidepressants for Treating Major Depression
• Abilify Therapy for Reducing Comorbid Substance Abuse
• A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
• Risperidone vs. Paroxetine for Panic Attacks
• The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity
• Use of Risperidone in ECT for Treatment Resistant Depression
• Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
• Treatment Choices for Improving Adherence and Outcome
• Switching to Duloxetine From Other Antidepressants
• A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain
• Duloxetine in the Treatment of Melancholic Depression
• Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine Trials
• A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder
• Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response
• Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression
• Treatment of Nicotine Dependence and Acute Depression
• Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?
• Mifepristone in Refractory Depression
• Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults
• Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
• Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
• Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder
• Sertraline vs. Venlafaxine XR
• The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram
• Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder
• Pharmacotherapy in Depression With Panic Spectrum
• Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression
• Treatment of Depression With Quetiapine
• Treatment of Major Depressive Disorder With Psychotic Features.
• Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant
• The Neurobiology of Depressive Illness
• Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
• Risperidone and Suicidality in Major Depressive Disorder
• Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
• Depression, Epinephrine, and Platelet Function
• The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
• Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression
• Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
• Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression
• Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
• Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome
• Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
• Chronos: the Use of Chronobiological Treatment in Depression
• An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
• Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
• Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder
• A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
• An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
• A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
• The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression
• Metyrapone as Additive Treatment in Major Depression
• Org 24448 to Treat Major Depression
• Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
• Study of Escitalopram in Adult Patients With Major Depressive Disorder
• The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
• Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
• A Study of Aripiprazole in Patients With Major Depressive Disorder
• Study Of GW679769 In Major Depressive Disorder
• A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
• A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
• A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder
• Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy
• A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
• Major Depressive Disorder In The Elderly
• Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder
• Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder
• Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder
• Lexapro and Pramipexole and to Treat Major Depression
• Rapid Antidepressant Effects of Yohimbine in Major Depression
• Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
• Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
• A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
• Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
• Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
• Depression Study In Elderly Patients
• PUFA Augmentation in Treatment of Major Depression
• Lethargic Depression Study
• Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
• Study of Duloxetine in Elderly Patients With Major Depressive Disorder
• An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
• An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder
• An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
• Study of Pharmacotherapy of Psychotic Depression
• Effects Of Antidepressants On Sexual Functioning In Adults
• Effects of Antidepressants on Sexual Functioning
• Major Depressive Disorder Study In Adults
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)
• Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
• A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
• Study Evaluating Venlafaxine ER in Recurrent Depression
• A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
• Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression
• Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
• Examination of a Soy-Based Supplement for Major Depression
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
• Clinical Trial of Memantine for Major Depression
• Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
• Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder
• The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
• Riluzole to Treat Major Depression
• Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes
• Treatment for Adolescents With Depression Study (TADS)
• Treatment of Major Depression With St. John's Wort (Hypericum)
• Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial
• Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder